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Oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of neurodegenerative diseases, with
the latter preceding the appearance of clinical symptoms. The energy failure resulting from mitochondrial dysfunction further
impedesbrainfunction,whichdemandslargeamountsofenergy.SchisandrinB(SchB),anactiveingredientisolatedfromFructus
Schisandrae, has been shown to aﬀord generalized tissue protection against oxidative damage in various organs, including the
brain, of experimental animals. Recent experimental ﬁndings have further demonstrated that Sch B can protect neuronal cells
againstoxidativechallenge,presumablybyfunctioningasahormeticagenttosustaincellularredoxhomeostasisandmitoenergetic
capacity in neuronal cells. The combined actions of Sch B oﬀer a promising prospect for preventing or possibly delaying the onset
of neurodegenerative diseases, as well as enhancing brain health.
1.The Role of Mitochondrial Dysfunction and
Mitoenergetic Failure in the Development of
Age-Related Neurodegenerative Diseases
Although the etiologies of age-related neurodegenerative
diseases are diﬀerent and multifactorial, mitochondrial dys-
function has been recognized as a common factor in the
pathogenesis of these diseases [1, 2]. The common mecha-
nisticfeaturesofmostage-relatedneurodegenerativediseases
involve the mitochondrial-derived free radical generation
and the existence of a hypometabolic state (i.e., a cellular
energy deﬁcit) which results from mitochondrial functional
impairment [3–6].
The brain is critically dependent on energy supply
in order to sustain various neuronal processes such as
induction of action potentials and neurotransmission, [7].
In this regard, mitochondria generate approximately 90% of
the required energy through oxidative phosphorylation, in
which the electron transport process unavoidably results in
reactive oxygen species (ROS) generation [8]. Thus, while
being the sites of ATP generation, mitochondria are also a
signiﬁcant source of ROS such as hydrogen peroxide (H2O2)
and superoxide anion (O2
.−)[ 9]. Functional impairment
of mitochondria, resulting in excessive ROS production
and mitoenergetic failure, can result in subtle pathological
alterations to neuronal cells. In this regard, aberrations at the
level of organelles involved in cellular energetics have been
implicated in more than 40 diﬀerent pathological conditions
[10].
Emerging evidence has shown that mitochondrial ROS-
induced oxidative stress is involved in the pathogenesis
of neurodegenerative diseases [2, 11, 12]. Mitochondrial
dysfunction involving electron transport chain (ETC) failure
and ROS-mediated cellular damage is common features of
Alzheimer’s disease (AD), Parkinson’s disease (PD), and
amyotrophic lateral sclerosis (ALS) [13–16]. ROS can harm
cellsbycausingrandomoxidativedamagetoessentialcellular
components including DNA, proteins, and lipids. The high
susceptibility of the brain to oxidative stress is mainly
due to the relative deﬁciency of antioxidant enzymes, such
as superoxide dismutase (SOD), Se-glutathione peroxidase
(GPX), glutathione reductase (GR), and catalase (CAT)
in this tissue [17, 18]. Furthermore, brain mitochondria
are particularly sensitive to oxidative damage and show2 Oxidative Medicine and Cellular Longevity
a slow turnover rate; the accumulation of dysfunctional
mitochondria,therefore,canfurtherexacerbatetheoxidative
stress in brain tissue [19].
In addition to serving as a cellular source of energy
to brain tissue, mitochondria also play a critical role in
other important cellular processes, including intermediary
metabolism, calcium homeostasis, intracellular signaling,
and apoptosis through the generation of intracellular oxi-
dants such as H2O2 [9]. Mitochondria-derived ROS can
aﬀect overall cellular and mitochondrial function by alter-
ing glutathione redox status and/or the posttranslational
modiﬁcation of proteins structure and function via oxida-
tive processes [20, 21]. Redox-sensitive signaling pathways,
such as glycogen synthase kinase (GSK) insulin signaling,
the C-Jun-NH2-terminal kinase (JNK) proapoptotic, and
protein kinase B (Akt) prosurvival pathways, are found
to be dysregulated during neurodegeneration associated
with enhanced mitochondrial ROS production [22–24]. The
release of oxidants (O2
.−,H 2O2, NO) from mitochondria
into the cytosol further results in chemical (posttransla-
tional) modiﬁcation of intracellular proteins subsequent to
the changes in cellular redox status. Under conditions of
oxidative/nitrosative stress, exposure of proteins to ROS
or reactive nitrogen species (RNS) can result in oxida-
tion/nitrosylation of protein thiols, nitration of tyrosine
residues, and S-glutathionylation involving the formation
of mixed disulﬁdes between protein sulfhydryls and glu-
tathione, all of which can lead to protein structural and
functional alterations. For instance, the posttranslational
modiﬁcation of key enzymes involved in energy metabolism,
such as pyruvate dehydrogenase (PDH), aconitase, and
succinyl-CoA transferase (SCOT), often causes a loss of
protein function and results in glucose hypometabolism
and mitoenergetic failure [3, 23, 25]. In this regard, several
clinical studies have shown that before the occurrence of
any pathological changes in the brain, impaired glucose
metabolism in cerebral tissues is the earliest and consistent
abnormality observed in AD and mild cognitive impairment
(MCI) [26]. At the molecular level, the oxidative stress-
induced impairment in mitochondrial energy-transducing
capacity can lead to the opening of mitochondrial perme-
ability transition (MPT) pores [27]. This process, which
is accompanied by a collapse of mitochondrial membrane
potential and energy production, can result in the reverse
operation of ATP synthase, thereby further accelerating ATP
depletion resulting in the loss of ion homeostasis, and
ultimately, necrotic cell death [28]. MPT pore opening also
causes the leakage of cytochrome c from mitochondria into
the cytoplasm and triggers a cascade of events such as
caspase-9 activation that eventually leads to mitochondrion-
drivenapoptosis[29].Insummary,enhancedoxidativestress
and mitoenergetic failure resulting from mitochondrial dys-
function can all collectively contribute to the pathogenesis of
neurodegenerative diseases.
In this paper, we will review the neuroprotective eﬀects
of schisandrin B (Sch B) and its potential application as
a hormetic agent for favorably inﬂuencing the course of
neurodegenerative diseases. In addition, we will discuss the
biochemical basis of the Sch B-aﬀorded neuroprotection and
its possible role in preventing mitoenergetic failure, thereby
improving brain health.
2.DietarySchisandrinBMitigates
Age-Related ImpairmentinMitochondrial
AntioxidantStatusandFunctional
CapacityinBrainTissues
SchBisthemostabundantdibenzocyclooctadienederivative
found in Fructus Schisandrae (FS), a traditional Chinese
herb commonly used for the treatment of viral and chemical
hepatitis. According to Traditional Chinese Medicine (TCM)
theory, FS is classiﬁed as a “Qi-invigoration” herb under
the “Yang” family. Holistically, while “Yang” is viewed as a
manifestation of body function supported by various organs,
“Qi” is regarded as a vital substance, which is fundamental
to life and provides energy for the human body [30]. FS is
believed to nourish the “Qi” of the heart, kidney, liver, lung,
and spleen, with improved energy utilization and increased
longevity. In order to validate this time-honored TCM the-
ory, various scientiﬁc investigations have been undertaken
in several laboratories, including our own, to investigate
the eﬀectiveness of Sch B in ameliorating impairments in
mitochondrial antioxidant status and functional capacity.
Early ﬁndings have conﬁrmed the beneﬁcial eﬀect of Sch B
onliverfunction,particularlyinenhancingthedetoxiﬁcation
of xenobiotics and the regeneration of damaged liver [31].
Emerging evidence demonstrates the protective eﬀect of Sch
Bagainstfree-radical-inducedtissueinjuryinvarioustissues,
including the brain [32–36].
Data from aging studies provide additional information
on the ability of Sch B to mitigate age-related impair-
ments in brain mitochondrial antioxidant status and func-
tional capacity. Progressive impairment in mitochondrial
antioxidant status and a decline in mitochondrial function
have been documented in brain tissue of aging rodents
[37, 38]. Decreases in the levels of mitochondrial reduced
glutathione (GSH) and α-tocopherol (α-TOC), as well as
the activities of GPX and manganese SOD (MnSOD) in
brain tissue are invariably associated with the increased
mitochondria-driven production of ROS as a function of
aging in experimental animals [37, 38]. In agreement with
TCM theory, experimental data has shown that long-term
dietary supplementation with Sch B signiﬁcantly enhances
mitochondrial antioxidant status, stimulates mitochondrial
respiratory function, and maintains mitochondrial struc-
tural integrity, as well as decreasing ROS production in
the brain of experimental animals [37, 38]. Correlation
analysis has further indicated that the protection aﬀorded
by Sch B against age-dependent decline in mitochon-
drial antioxidant components, particularly MnSOD, may
be relevant to survival enhancement [37]. MnSOD has
been recognized as a major antioxidant enzyme protecting
the brain against both oxidative and nitrative stress by
eliminating O2
.− and preventing the generation of highly
reactive peroxynitrite (ONOO−) arising from the reaction
between NO with O2
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stress have been implicated in pathogenesis of neurode-
generative conditions such as AD, PD, and Huntington’s
disease (HD) [39]; animals with MnSOD deﬁciency have
been shown to be more vulnerable to the mitochondrial
neurotoxin malonate, 3-nitropropionic acid, and 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), both of which
can induce oxidative stress [40]. Furthermore, the alteration
of redox status as a result of MnSOD-mediated ROS
eliminationhasalsobeenproposedtoregulatespeciﬁcstress-
responsive genes related to antiapoptotic substances, such as
cyclin B1, cyclin A, GADD153, and 14-3-3 zeta [41].
The enhancement of mitochondrial function (i.e., res-
piratory activity) by Sch B has been shown to stimulate
mitochondrial ATP generation in aging mouse brains [37].
Improvement in respiratory function has been proposed to
stimulate the activity of sirtuin [42], which can activate
antiapoptotic, anti-inﬂammatory, and antistress responses,
as well as modulate the aggregation of proteins associated
with neurodegenerative conditions, thereby preventing or
delaying the onset of neurological damage [43]. Enhanced
regeneration of NAD as a result of Sch B-induced respi-
ratory functional improvement can also be beneﬁcial to
neuronal health. Studies have demonstrated that exposure
of neuronal cells to NAD can prevent axonal degeneration,
a pathophysiological process that often precedes the death of
neuronal cell bodies in PD and AD, through the activation of
the NAD-dependent deacetylase sirtuin-1 (SIRT1) pathway
[44, 45].
3. Neuroprotection Afforded by SchisandrinB
In addition to the aforementioned aging research, studies
utilizing various models of brain oxidative challenge have
further advanced our understanding of the neuroprotective
eﬀect of Sch B against oxidative insult. In the mouse
model of cerebral damage induced by the prooxidant
tertbutylhydroperoxide (t-BHP), Sch B treatment prevented
the increase in cerebral lipid peroxidation and impair-
ment in GSH antioxidant status produced by intracere-
broventricular injection of t-BHP [34]. The restoration of
GSH levels by Sch B is important for neuronal viabil-
ity because an imbalanced glutathione redox status can
trigger the sulfhydryl groups of cysteine sulﬁnic acids
to react with other sulfhydryl groups, including that of
glutathione, with the resultant formation of disulﬁdes or
mixed disulﬁdes. The modiﬁcation of protein sulfhydryl
groups can lead to alterations in protein function, with
disruption in normal cellular physiology, as has been
shown in the inactivation of the SH-group containing
enzyme glucose 6-phosphate dehydrogenase (G6DPH) by
ROS [46]. Transgenic overexpression of G6PDH in mouse
dopaminergic nigrostriatal neurons has been shown to
reduce their sensitivity to MPTP, presumably through
increasing the activity of this rate-limiting enzyme in the
hexose monophosphate shunt, which provides NADPH
required for the regeneration of GSH from its oxidized form
and sulfhydryl groups of oxidatively modiﬁed antioxidant
enzymes [47].
In a rat model of cerebral ischemia/reperfusion (I/R)
injury induced by clamping of both carotid arteries in
anesthetized animals, the neuroprotective property of Sch
B has been shown to be associated with the maintenance
of antioxidant status as well as the structural integrity
of mitochondria [32]. The neuronal injury caused by I/R
challenge involves pathophysiological mechanisms such as
ROS production and intracellular calcium overload; the
resultant perturbation of cellular redox homeostasis and
mitochondrial permeability transition pore opening eventu-
ally leads to necrotic and/or apoptotic cell death [48]. Long-
term treatment with Sch B (10mg/kg/day, p.o., for 15 days)
has been shown to aﬀord protection in the abovementioned
model of I/R-induced cerebral injury; as evidenced by a
signiﬁcant increase the percentage of viable tissue after I/R
challenge, which was determined by quantifying the area of
2,3,8-triphenyl tetrazolium chloride-stained tissue in brains
of control and Sch B-pretreated rats [32]. The protection was
associated with enhancement of mitochondrial antioxidant
components and preservation of mitochondrial integrity, as
evidenced by increased GSH, α-TOC levels, and MnSOD
activity as well as a reduced sensitivity of the Ca2+-induced
permeability transition and a reduction in cytochrome c
release [32]. The preservation of mitochondrial integrity by
long-term Sch B treatment is of crucial importance for the
mitoenergeticcapacityofcerebralmitochondria.Thisnotion
is supported by the observation that the ATP-generating
capacity of cerebral mitochondria was increased by long-
term Sch B treatment in brain tissue of both control and I/R-
challenged rats [32].
Recently, Giridharan et al. have demonstrated that Sch B
prevents memory deﬁcits in mice induced by scopolamine,
a muscarinic antagonist that induces central cholinergic
blockade [36]. Since cholinergic neurotransmission in the
basal forebrain is believed to play an important role in
learning and memory, scopolamine toxicity may provide
a useful model of cognitive impairment in rodents and
humans [36]. The scopolamine-induced cognitive deterio-
ration resembles the memory disturbances observed in AD,
which are associated with an increase in acetylcholinesterase
(AChE) activity and decreased acetylcholine levels [49]. In
the aforementioned study, Sch B treatment signiﬁcantly
inhibited AChE activity, resulting in increased acetylcholine
levels in the brain, accompanied by an amelioration of the
learning and memory impairment caused by scopolamine.
Although the detailed inhibitory mechanism of Sch B on
AChE remains to be investigated, it was postulated that
metabolites of Sch B (see below) may be responsible for
the AChE inhibition [36]. The neuroprotective eﬀects of Sch
B were also found to be closely related to its antioxidant
activity, in which the antioxidant depletion associated with
scopolamine toxicity was ameliorated by Sch B treatment, as
indicated by enhancements in GSH levels, GPX, and SOD
activities as well as a reduction in malondialdehyde and
nitrite levels in brain tissue [36].
Taken together, the beneﬁcial eﬀects of Sch B on mito-
chondrial antioxidant status and mitochondrial function
may suggest a new therapeutic approach for the prevention4 Oxidative Medicine and Cellular Longevity
and/or treatment neurodegeneration, thereby promoting
brain health in aging individuals.
4. Biochemical Mechanism Underlying
SchisandrinB CytoprotectionAgainst
OxidantInjuryinNeuronalCells
Sch B is a dibenzocyclooctadiene derivative with one
methylenedioxy group which can be dealkylated by a
cytochrome P-450 (CYP-) catalyzed reaction (Figure 1). In
vivo, Sch B was metabolized to yield three main phase I
metabolites, in which several oxidation routes appeared to
be involved: (1) hydroxylation of an alkyl substitute and
(2) demethylation of the OCH3 groups on the aromatic
rings [50]. The metabolites were detectable in bile and urine
of rats. Sch B could also be demethylated by demethylase
presented in red blood cells and then further metabolized
to produce phenolic hydroxyl group [51]. The metabolism
of Sch B ultimately leads to the formation of a quinone and
a subsequent low level ROS production via redox cycling
[52, 53]. The modest amount of ROS generated during
Sch B metabolism has been shown to elicit a glutathione
antioxidant response, which results in an enhancement of
glutathione antioxidant status that is closely associated with
a decreased susceptibility of various tissues, including the
brain, to oxidative injury [32, 54, 55].
The causal relationship between Sch B-induced GSH
enhancement and its cytoprotection against oxidative injury
in neuronal cells is further supported by a recent study
in diﬀerentiated PC12 dopaminergic neuronal cells [56].
Paraquat (PQ), a Parkinsonism-inducing agent, was used to
induce oxidative injury in diﬀerentiated PC12 cells, and the
extent of neuronal damage, as indicated by GSH depletion
and cell death, was signiﬁcantly reduced by pretreatment
with (−)Sch B, a potent Sch B stereoisomer [56]. The
cytoprotective eﬀect of (−)Sch B in PQ-challenged cells
was abrogated by inhibitors of γ-glutamylcysteine ligase
(GCL) and GR, suggesting the crucial involvement of GSH
regeneration and GSH synthesis in the protection against
oxidative stress [56]. Further investigations in PC12 cells
subjected to an acute t-BHP challenge have revealed that
while the initial GSH depletion induced by the peroxide was
reduced through the GR-catalyzed regeneration of GSH in
(−)Sch B-pretreated cells, the subsequent enhancement of
GSH recovery was mainly mediated by the GCL-catalyzed
synthesis of GSH [56]. The results suggested that (−)Sch B
treatment may increase the resistance of dopaminergic cells
to oxidative stress both by reducing the extent of oxidant-
induced GSH depletion and enhancing GSH recovery. A
comprehensive study using cultured cell lines derived from
various tissues has further demonstrated that the enhance-
ment of GR-mediated GSH regeneration is a universal
protective mechanism aﬀorded by Sch B in response to an
acute oxidant challenge. The study has also shown that acute
t-BHP-induced GSH depletion is signiﬁcantly reduced by
Sch B treatment, in which the activity of GR was found
to be enhanced [57]. This ﬁnding is consistent with the
postulation that GR-catalyzed GSH regeneration is crucial
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Figure 1: Chemical structures of schisandrin B.
for the maintenance of cellular glutathione redox status, and
hence cell survival, even in the absence of oxidative stress
[58, 59].
Although the molecular mechanism underlying Sch
B-induced neuroprotection remains to be elucidated, the
low levels of ROS produced during CYP-mediated Sch B
metabolism have been shown to activate several diﬀerent
redox-sensitive signal transduction pathways, with the elic-
iting of protective cellular responses [60, 61]. Our laboratory
has shown recently that (−)Sch B caused a dose-dependent
and sustained increase in ROS production as well as a time-
dependent activation of mitogen-activated protein kinase
(MAPK), particularly extracellular signal-regulated kinases
(ERK)1/2 [60, 61]. The MAPK activation was followed
by an enhanced translocation of NF-E2-related factors 2
(Nrf2) to the nucleus and the eliciting of a glutathione-
dependent antioxidant response in cultured hepatocytes
and cardiomyocytes [60, 61]. Nrf2 functions as a redox-
sensitive transcription factor that is translocated from the
cytosol to the nucleus upon phosphorylation by upstream
kinase and then binds to the antioxidant response element
consensus sequence to induce a glutathione antioxidant
response through the expression of antioxidant proteins
such as GR, GPX, and glutathione transferase (GST). Since
the eliciting of adaptive responses to oxidative stress often
requires one or more members of the MAPK cascade,
the possible involvement of oxidative stress-sensitive c-Jun
N-terminal kinases (JNK) and p38 MAPK (p38) kinases
in the neuronal model cannot be excluded. In addition
to MAPK-mediated phosphorylation, Nrf2 has also been
shown to be phosphorylated by protein kinase C (PKC)
or phospoinositol-3 kinase (PI3K) under conditions of
oxidative stress, and the activation of two or more of these
pathways may be required to achieve cytoprotection in a cell
type- and stimulant-dependent manner [62]. Therefore, the
information obtained from hepatocytes and cardiomyocytes,
when viewed in the light of established biochemical mecha-
nismoftheSchB-inducedglutathione-dependentprotection
observed in neurons, suggests a new approach for future
investigation of the involvement of JNK, p38, PKC, and/orOxidative Medicine and Cellular Longevity 5
PI3K in the Nrf2-mediated signaling pathways in Sch B-
induced neuroprotection.
A recent study of Sch B protection against cisplatin (cis-
diamminedichloroplatinum II, cDDP)-induced neurotoxic-
ity has revealed the involvement of nuclear factor Kappa
B( N F - κB) [35]. cDDP is a chemotherapeutic agent used
for the treatment of various solid tumors. However, its
clinical use is limited by its adverse eﬀects, particularly ROS-
mediated neurotoxicity which can produce severe cognitive
dysfunction [63]. As assessed by the passive avoidance
performance task test, cDDP-treated mice were found to
developbothshort-termandlong-termmemorydeﬁcitsthat
could be signiﬁcantly improved by Sch B treatment. In this
study, the ability of Sch B to ameliorate memory deﬁcits was
associatedwithitsabilitytosuppresstheactivationofNF-κB.
The inhibition of NF-κB by Sch B was further demonstrated
in this study by the reduction of the downstream activation
of p53 and caspase 3. NF-κB has been well established as
a common mediator of cDDP-induced cytotoxicity and has
been implicated in many other neurodegenerative diseases
such as AD, PD, and HD [35]. Therefore, the ability of
Sch B to modulate NF-κB, p53, and caspase-3 signaling
pathways further strengthens the prospect of its potential use
for preventing or ameliorating neurodegenerative disorders.
5.PotentialRole of SchisandrinB
asaHormeticAgentinPreventing
Mitoenergetic Failure and Improving
Brain Health
To date, the use of antiapoptotic agents to prevent neu-
rodegenerative disorders has not been successful, mainly
due to the toxicity and the associated risk of carcinogen-
esis of the compounds in question. On the other hand,
the eﬀectiveness of free radical scavenging antioxidants in
achieving neuroprotection requires high concentrations that
are not readily achievable in brain tissue. Therefore, in recent
years, there has been a growing interest, as supported by
a large volume of experimental evidence, in the possible
use of hormetic agents as a novel therapeutic alternative in
preventing various pathological conditions, including those
associated with neurodegeneration [64].
By deﬁnition, hormesis refers to an adaptive response
of cells and organism to a moderate stress and a hormetic
response is a biphasic dose-response phenomenon in which
a chemical/stimulus (e.g., ionizing radiation, heat stress,
or ROS) has a beneﬁcial eﬀect on maintaining cellular
homeostasis at low doses/levels but causes a toxic eﬀect at
high doses/levels [65, 66]. A compelling body of evidence
suggests that the low-level mitochondrial ROS-induced
oxidativestressproducedbycaloricrestriction,hypothermia,
or hyperbaric oxygen conditions elicits adaptive cellular sig-
naling/responses that can result in an increased stress resis-
tance, which maintains homeostasis and promotes longevity,
thus providing the basis of mitochondrial hormesis or
“mitohormesis” [67–70]. However, all the aforementioned
conditions are generally impractical to achieve in humans.
Therefore, the approach to achieving mitohormesis using
hormetic agents to enhance endogenous mitochondrial anti-
oxidant status and functional capacity may oﬀer a promising
prospect for preventing or possibly delaying the onset of age-
related neurodegenerative diseases.
In this regard, Sch B acts as a hormetic agent in
cultured cells, with cytoprotective eﬀects predominating
at low concentrations and cytotoxicity occurring at high
concentrations [71, 72]. Pharmacokinetic study on Sch B
showed that a mean value of 96.1 ± 14.1ng/mL(∼0.25μM)
of maximum plasma drug concentration and a half-life
of about 2 hours can be achieved by oral administration
of 15mg Sch B to healthy male subjects [73]. Toxicology
study also demonstrated that the LD50 values of orally or
intraperitoneallyadministeredpetroleumetherextractofFS,
which contains 40% (w/w) lignans, were 10.5 and 4.4g/kg,
respectively [74]. No death was observed by administration
of a single oral dose of Sch B at 2g/kg in rats [75].
Furthermore, an intragastric dose of 200mg of Sch B for
30 days did not signiﬁcantly aﬀect body weight, blood
parameters, and histological parameters of major organs in
mice [75]. When given at 10mg/kg daily for 4 weeks, Sch B
also did not aﬀect appetite, liver, or kidney functions, as well
as liver histological parameters in dogs [75]. Taken together,
Sch B treatment is generally considered to be safe; a single
oral dose (0.8g/kg), multiple doses (200mg/kg × 30) as well
as dietary supplementation (0.012%, w/w, starting from 9
months of age until death) did not cause any undetectable
adverse eﬀects in rodents [34, 37].
As far as bioavailability is concerned, the delivery of
therapeutic agents across the blood-brain barrier (BBB)
represents a major challenge to therapeutic agents aimed
at treating brain disorders. This leads to the failure of
therapeutic agents that might otherwise be eﬀective if they
can penetrate the BBB. Although whether or not Sch B
or its metabolites can penetrate the BBB requires further
investigation; the aforementioned observations from Sch B
in preventing diﬀerent types of oxidative stress-induced neu-
ronal injury have provided substantial evidence to support
the postulation that Sch B can cross the BBB and exert its
actions in brain tissue.
In addition to safety and bioavailability concerns, the
ability of a hormetic agent to enhance mitoenergetic capacity
is another indispensable property for achieving mitohorme-
sis in brain and promoting brain health. Mitoenergetic
failure has emerged as a focus of research on the pathol-
ogy of various age-related neurodegenerative diseases, with
numerous investigations attempting to identify potential
therapeutic agents that might enhance mitochondrial func-
tional capacity. While health supplements, such as lipoic
acid, curcumin, and resveratrol, have all been shown to
increase antioxidant capacity by functioning as free radical
scavengers, their eﬀectiveness in enhancing mitochondrial
function and thereby helping to maintain neuronal viability
has not been fully investigated. On the other hand, the
well-established mitochondrial antioxidant and mitoener-
getic sparing properties of Sch B make it a particularly
promising candidate for promoting brain health. Results
fromourrecentinvestigationhavefurtherdemonstratedthat6 Oxidative Medicine and Cellular Longevity
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Figure 2: The role of Schisandrin B as a hormetic agent in preventing mitoenergetic failure and neurodegeneration (please refer to the text
for details).
Sch B treatment can attenuate the oxidative stress induced
by 3-nitroproponic acid, a potent irreversible inhibitor of
mitochondrial succinate dehydrogenase that has been used
in experimental models of HD, in diﬀerentiated PC12 cells
and prevent the oxidative stress-induced energy crisis by
suppressing the activation of the JNK signaling pathway and
the consequent inhibition of PDH [76], a key bioenergetic
enzyme which bridges anaerobic and aerobic brain energy
metabolism. This observation supports the role of Sch B in
enhancing glucose utilization in the brain. Abnormalities in
brain glucose metabolism have been implicated in the early
stages of various neurodegenerative disease development
[77].
As of today, investigations on the beneﬁcial eﬀects of
Sch B on neurodegenerative disorders remain predomi-
nantly preclinical. However, substantial evidence of Sch B
on reducing oxidative stress-induced neuronal injury has
shed light on its potential use as a therapeutic agent for
neurodegenerative diseases. Recently, clinical studies have
adopted the concept of disease modiﬁcation, in which the
improvement on long-term clinical outcomes, presumably
byslowingdowndiseaseprogression,isevaluatedinpatients.
In this connection, the reduction of free radical-induced
oxidative stress represents a novel therapeutic approach
for retarding the progression of neurodegenerative diseases,
such as PD, in that MAO-B inhibitors were used in the
therapy in order to prevent oxidative stress generated
by the transformation of dopamine to its metabolites
3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenyl-
acetic acid [78]. This approach has favorably inﬂuenced the
progression of PD, as assessed by both motor and nonmotor
symptoms [79], suggesting the causal relationship between
reduction of oxidative stress and neuroprotection. As such,
the ability of Sch B to retard disease progression would
be a primary endpoint in clinical trial. Clinical parameters
that are more relevant to pathogenesis of neurodegenerative
diseases should be assessed in the trials.
Taken together, we posit that Sch B can function as a
hormetic agent by eliciting a cellular antioxidant response,
with resultant enhancement of cellular redox capacity and
mitochondrial functional integrity, thereby maintaining cel-
lular homeostasis against oxidative challenge. The occur-
rence of deleterious posttransitional modiﬁcation of key
bioenergetic enzymes can also be reduced by the improved
cellular redox status. The abilities of Sch B to enhance
mitoenergetic capacity and fortify antioxidant defense oﬀer
a promising prospect in preventing or delaying the onset
of neurodegenerative disorders, possibly by inhibiting cell
apoptosis (see Figure 2).
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